Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $220.00 by Analysts at Wells Fargo & Company

Key Points

• Wells Fargo cut Alnylam’s price target to $220 from $253 while maintaining an “equal weight” rating; the new target implies approximately 29.3% upside from the previous close.
• Analyst sentiment remains broadly positive but has weakened, with MarketBeat reporting a “Moderate Buy” consensus and an average price target of $329.81. Several firms recently lowered targets or downgraded the stock.
• Alnylam’s third-quarter revenue rose 16.7% year over year to $1.46 billion, beating estimates, while reported EPS of $16.26 was boosted by a major tax benefit. Shares closed at $170.14, near their 12-month low, amid concerns about slowing U.S. sales growth for Amvuttra and Onpattro.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price target cut by stock analysts at Wells Fargo & Company from $253.00 to $220.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an "equal weight" rating on the biopharmaceutical company's stock. Wells Fargo & Company's price target suggests a potential upside of 29.30% from the stock's previous close.

Other equities analysts also recently issued research reports about the company. Truist Financial reduced their price objective on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a "buy" rating on the stock in a research report on Tuesday, August 4th. BMO Capital Markets reissued an "outperform" rating and set a $290.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday. Zacks Research lowered shares of Alnylam Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, October 23rd. Oppenheimer reduced their target price on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an "outperform" rating on the stock in a research report on Friday, July 31st. Finally, TD Cowen reissued a "buy" rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $329.81.

Alnylam Pharmaceuticals Stock Performance

ALNY traded down $3.86 on Friday, reaching $170.14. The stock had a trading volume of 2,531,587 shares, compared to its average volume of 1,496,795. The business's 50-day moving average price is $237.78 and its two-hundred day moving average price is $287.22. The company has a market cap of $22.77 billion, a P/E ratio of 31.68 and a beta of 0.28. Alnylam Pharmaceuticals has a 12-month low of $167.16 and a 12-month high of $479.79. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, topping analysts' consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.43 billion. During the same period in the prior year, the business posted $2.90 earnings per share. The firm's revenue for the quarter was up 16.7% on a year-over-year basis. Sell-side analysts forecast that Alnylam Pharmaceuticals will post 6.43 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the transaction, the executive vice president owned 12,807 shares of the company's stock, valued at $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Legal & General Group Plc purchased a new position in Alnylam Pharmaceuticals in the second quarter valued at about $278,321,000. Bank of New York Mellon Corp purchased a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth $148,128,000. Canada Pension Plan Investment Board acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter worth $100,618,000. Korea Investment CORP acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter worth $74,553,000. Finally, Wellington Management Group LLP grew its stake in shares of Alnylam Pharmaceuticals by 9.0% during the second quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company's stock valued at $635,296,000 after acquiring an additional 174,482 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 16.7% year over year to $1.46 billion, exceeding the $1.43 billion consensus estimate. Reported EPS of $16.26 also surpassed expectations, although the result was significantly boosted by a roughly $1.9 billion tax benefit. Alnylam Q3 earnings and revenue results
• Positive Sentiment: Management reaffirmed its fiscal 2026 outlook and anticipates $4.2 billion to $4.5 billion in TTR product sales, supporting the company’s near-term revenue base. Alnylam TTR sales outlook and TRITON-CM expansion
• Positive Sentiment: Needham maintained a “buy” rating, with a reduced $243 price target that still implies substantial upside, while Alnylam highlighted continued progress across its RNAi pipeline. Needham analyst rating
• Neutral Sentiment: Alnylam expanded the Phase 3 TRITON-CM study of nucresiran to approximately 2,250 patients while retaining an expected launch timeline around 2030. The larger trial may improve the evidence base but also raises development costs and reinforces the long wait for a potential revenue contribution. Alnylam pipeline and nucresiran update
• Negative Sentiment: Investors reacted negatively to indications that U.S. Amvuttra and Onpattro sales growth is slowing, reducing the impact of the earnings beat and raising concerns about the pace of future growth. Alnylam sales growth analysis
• Negative Sentiment: Stifel downgraded ALNY from “buy” to “hold” with a $225 target, followed by Bernstein’s downgrade from “outperform” to “market perform” with a $199 target. Although both targets remain above the recent trading level, the rating changes signal reduced conviction and added selling pressure. Stifel downgrade

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company's therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam's marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.